TP53 共突变：EGFR 突变肺腺癌耐药演化风险
类型: 原始研究 / 分子队列 发表日期: 2022-03-21 入库日期: 2026-05-21 来源: PubMed / Journal of Thoracic Oncology 标签: EGFR L858R, TP53, 奥希替尼耐药, 克隆演化, NGS
Citation
Blakely CM, Watkins TBK, Wu W, et al. Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma. Journal of Thoracic Oncology. 2022. PMID: 35331964. DOI: 10.1016/j.jtho.2021.06.004
Why it matters for mom
Mom has a baseline TP53 mutation. TP53 is not directly targetable in routine care, but it changes the mental model: EGFR-mutant disease with TP53 alteration may evolve resistance more aggressively and heterogeneously than EGFR-only disease.
For the family, this supports a low threshold for repeat molecular testing at progression and for interpreting mixed response seriously.
Practical takeaways
- TP53 alteration strengthens the case for repeat NGS when progression is confirmed.
- Resistance can be heterogeneous; a single blood test may miss histologic transformation or site-specific biology.
- The result should be used for surveillance and diagnostic planning, not as a standalone treatment choice.
Questions for doctors
- At progression, would tissue biopsy add value beyond ctDNA?
- Is there any sign that different lesions are behaving differently?
- Which resistance mechanisms should the NGS panel cover: MET amplification, EGFR C797S/T790M, HER2, fusions, BRAF/PIK3CA, and transformation markers?